Advertisement

Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know

Published:February 06, 2021DOI:https://doi.org/10.1016/j.dld.2021.01.015

      Abstract

      Background

      The kidney function monitoring is recommended in routine practice to detect 5-aminosalicylic acid (5-ASA) related nephrotoxicity, although is not standardized. The optimal monitoring is unknown, especially the best timing and which tests to perform. We summarized why, how, and when to perform the monitoring for patients treated with 5-ASA and provided an overview of the current guidelines on this topic.

      Method

      Relevant studies on this topic were searched in PubMed, Embase, and Web of Science databases from July to August 2020.

      Results

      Serum creatinine, the estimated glomerular filtration rate, and 24-h proteinuria are the 3 main tests used for the monitoring in daily practice. Regarding the timing, several monitoring strategies have been proposed and guidelines are available too, but they provide conflicting information. To date, there is no medical evidence-based that one strategy is better than another. Comorbidities, chronic renal disease, use of nephrotoxic drugs or concomitant steroid therapy also impact the nephrotoxicity risk. Based on the literature review we proposed a kidney function monitoring strategy to guide physicians in clinical practice.

      Conclusion

      A baseline assessment should be performed in all patients treated with 5-ASA. The monitoring should be carried out according to the other nephrotoxic factors. A tight monitoring may reduce morbidity and mortality of drug nephrotoxicity.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Harbord M.
        • Eliakim R.
        • Bettenworth D.
        • et al.
        Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management.
        J Crohns Colitis. 2017; 11: 769-784
        • Torres J.
        • Bonovas S.
        • Doherty G.
        • et al.
        ECCO guidelines on therapeutics in Crohn's disease: medical treatment.
        J Crohns Colitis. 2020; 14: 4-22
        • Lasch K.
        • Liu S.
        • Ursos L.
        • et al.
        Gastroenterologists’ perceptions regarding ulcerative colitis and its management: results from a large-scale survey.
        Adv Ther. 2016; 33: 1715-1727
        • Rubin D.T.
        • Siegel C.A.
        • Kane S.V.
        • et al.
        Impact of ulcerative colitis from patients’ and physicians’ perspectives: results from the UC: NORMAL survey.
        Inflamm Bowel Dis. 2009; 15: 581-588
        • Gomollón F.
        • Dignass A.
        • Annese V.
        • et al.
        3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management.
        J Crohns Colitis. 2017; 11: 3-25
        • Loftus E.V.
        • Kane S.V.
        • Bjorkman D.
        Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
        Aliment Pharmacol Ther. 2004; 19: 179-189
        • Birketvedt G.S.
        • Berg K.J.
        • Fausa O.
        • Florholmen J.
        Glomerular and tubular renal functions after long-term medication of sulphasalazine, olsalazine, and mesalazine in patients with ulcerative colitis.
        Inflamm Bowel Dis. 2000; 6: 275-279
        • Corrigan G.
        • Stevens P.E.
        Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.
        Aliment Pharmacol Ther. 2000; 14: 1-6
        • Calder I.C.
        • Funder C.C.
        • Green C.R.
        • et al.
        Comparative nephrotoxicity of aspirin and phenacetin derivatives.
        Br Med J. 1971; 4: 518-521
        • Calder I.C.
        • Funder C.C.
        • Green C.R.
        • et al.
        Nephrotoxic lesions from 5-aminosalicylic Acid.
        Br Med J. 1972; 1: 152-154
        • Bilyard K.G.
        • Joseph E.C.
        • Metcalf R.
        Mesalazine: an overview of key preclinical studies.
        Scand J Gastroenterol Suppl. 1990; 172: 52-55
        • Noble E.
        • Janssen L.
        • Dierickx P.J.
        Comparative cytotoxicity of 5-aminosalicylic acid (mesalazine) and related compounds in different cell lines.
        Cell Biol Toxicol. 1997; 13: 445-451
        • Bennett W.M.
        • Henrich W.L.
        • Stoff J.S.
        The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations.
        Am J Kidney Dis. 1996; 28: S56-S62
        • Clive D.M.
        • Stoff J.S.
        Renal syndromes associated with nonsteroidal antiinflammatory drugs.
        N Engl J Med. 1984; 310: 563-572
        • Duggin G.G.
        Mechanisms in the development of analgesic nephropathy.
        Kidney Int. 1980; 18: 553-561
        • Van Staa T.P.
        • Travis S.
        • Leufkens H.G.M.
        • Logan R.F.
        5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study.
        Gastroenterology. 2004; 126: 1733-1739
        • Oikonomou K.A.
        • Kapsoritakis A.N.
        • Stefanidis I.
        • Potamianos S.P.
        Drug-induced nephrotoxicity in inflammatory bowel disease.
        Nephron Clin Pract. 2011; 119: c89-c94
        • World M.J.
        • Stevens P.E.
        • Ashton M.A.
        • Rainford D.J.
        Mesalazine-associated interstitial nephritis.
        Nephrol Dial Transplant. 1996; 11: 614-621
        • Barbour V.M.
        • Williams P.F.
        Nephrotic syndrome associated with sulphasalazine.
        BMJ. 1990; 301: 818
        • Dignass A.
        • Lindsay J.O.
        • Sturm A.
        • et al.
        Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.
        J Crohns Colitis. 2012; 6: 991-1030
        • Elseviers M.M.
        • D'Haens G.
        • Lerebours E.
        • et al.
        Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy?.
        Clin Nephrol. 2004; 61: 83-89
        • Gisbert J.P.
        • González-Lama Y.
        • Maté J.
        5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.
        Inflamm Bowel Dis. 2007; 13: 629-638
        • Thuluvath P.J.
        • Ninkovic M.
        • Calam J.
        • Anderson M.
        Mesalazine induced interstitial nephritis.
        Gut. 1994; 35: 1493-1496
        • Haas M.
        • Shetye K.R.
        Acute renal failure in a 53-year-old woman with Crohn's disease treated with 5-aminosalicylic acid.
        Am J Kidney Dis. 2001; 38: 205-209
        • Frandsen N.E.
        • Saugmann S.
        • Marcussen N.
        Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.
        Nephron. 2002; 92: 200-202
        • Travis S.P.L.
        • Stange E.F.
        • Lémann M.
        • et al.
        European evidence-based Consensus on the management of ulcerative colitis: current management.
        J Crohns Colitis. 2008; 2: 24-62
        • Kornbluth A.
        • Sachar D.B.
        • Practice Parameters Committee of the American College of Gastroenterology
        Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee.
        Am J Gastroenterol. 2010; 105: 501-523
        • Ko C.W.
        • Singh S.
        • Feuerstein J.D.
        • et al.
        AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis.
        Gastroenterology. 2019; 156: 748-764
        • Singh S.
        • Feuerstein J.D.
        • Binion D.G.
        • Tremaine W.J.
        AGA technical review on the management of mild-to-moderate ulcerative colitis.
        Gastroenterology. 2019; 156 (.e29): 769-808
        • Bressler B.
        • Marshall J.K.
        • Bernstein C.N.
        • et al.
        Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus.
        Gastroenterology. 2015; 148 (.e3): 1035-1058
        • Lamb C.A.
        • Kennedy N.A.
        • Raine T.
        • et al.
        British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
        Gut. 2019; 68: s1-s106
        • Muller A.F.
        • Stevens P.E.
        • McIntyre A.S.
        • et al.
        Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom.
        Aliment Pharmacol Ther. 2005; 21: 1217-1224
        • Cunliffe R.N.
        • Scott B.B.
        Review article: monitoring for drug side-effects in inflammatory bowel disease.
        Aliment Pharmacol Ther. 2002; 16: 647-662
        • Gisbert J.P.
        • Luna M.
        • González-Lama Y.
        • et al.
        Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study.
        Gastroenterol Hepatol. 2008; 31: 477-484
        • Jairath V.
        • Hokkanen S.R.K.
        • Guizzetti L.
        • et al.
        No increased risk of nephrotoxicity associated with 5-aminosalicylic acid in IBD: a population-based cohort and nested case-control study.
        Aliment Pharmacol Ther. 2019; 50: 416-424
        • Toffaletti J.G.
        • McDonnell E.H.
        Variation of serum creatinine, cystatin C, and creatinine clearance tests in persons with normal renal function.
        Clin Chim Acta. 2008; 395: 115-119
        • Zallot C.
        • Billioud V.
        • Frimat L.
        • et al.
        5-Aminosalicylates and renal function monitoring in inflammatory bowel disease: a nationwide survey.
        J Crohns Colitis. 2013; 7: 551-555
        • Weislinger L.
        • Guillo L.
        • D'Amico F.
        • et al.
        Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with 432 inflammatory bowel disease.
        Eur J Gastroenterol Hepatol. 2020
        • Arend L.J.
        • Springate J.E.
        Interstitial nephritis from mesalazine: case report and literature review.
        Pediatr Nephrol. 2004; 19: 550-553
        • Mehta R.P.
        Acute interstitial nephritis due to 5-aminosalicylic acid.
        CMAJ. 1990; 143: 1031-1032
        • De Broe M.E.
        • Stolear J.C.
        • Nouwen E.J.
        • Elseviers M.M.
        5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link?.
        Nephrol Dial Transplant. 1997; 12: 1839-1841
        • Corica D.
        • Romano C.
        Renal involvement in inflammatory bowel diseases.
        J Crohns Colitis. 2016; 10: 226-235
        • Izzedine H.
        • Simon J.
        • Piette A.-.M.
        • et al.
        Primary chronic interstitial nephritis in Crohn's disease.
        Gastroenterology. 2002; 123: 1436-1440
        • Oikonomou K.
        • Kapsoritakis A.
        • Eleftheriadis T.
        • et al.
        Renal manifestations and complications of inflammatory bowel disease.
        Inflamm Bowel Dis. 2011; 17: 1034-1045
        • Treffel M.
        • Champigneulle J.
        • Meibody F.
        • et al.
        Tubulointerstitiel nephritis and Crohn's disease, nephrotoxicity or extraintestinal manifestation of Crohn's disease? About a case.
        Nephrol Ther. 2019; 15: 59-62
        • Herrlinger K.R.
        • Noftz M.K.
        • Fellermann K.
        • et al.
        Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use.
        Aliment Pharmacol Ther. 2001; 15: 363-369
        • Riley S.A.
        • Lloyd D.R.
        • Mani V.
        Tests of renal function in patients with quiescent colitis: effects of drug treatment.
        Gut. 1992; 33: 1348-1352
        • Mahmud N.
        • Stinson J.
        • O'Connell M.A.
        • et al.
        Microalbuminuria in inflammatory bowel disease.
        Gut. 1994; 35: 1599-1604
        • Mahmud N.
        • McDonald G.S.
        • Kelleher D.
        • Weir D.G.
        Microalbuminuria correlates with intestinal histopathological grading in patients with inflammatory bowel disease.
        Gut. 1996; 38: 99-103
        • Kreisel W.
        • Wolf L.M.
        • Grotz W.
        • Grieshaber M.
        Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease.
        Eur J Gastroenterol Hepatol. 1996; 8: 461-468
        • Fraser J.S.
        • Muller A.F.
        • Smith D.J.
        • et al.
        Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy.
        Aliment Pharmacol Ther. 2001; 15: 1131-1137
        • Poulou A.C.
        • Goumas K.E.
        • Dandakis D.C.
        • et al.
        Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid?.
        World J Gastroenterol. 2006; 12: 739-746
        • McCloskey O.
        • Maxwell A.P.
        Diagnosis and management of nephrotic syndrome.
        Practitioner. 2017; 261: 11-15
        • Vart P.
        • Grams M.E.
        Measuring and assessing kidney function.
        Semin Nephrol. 2016; 36: 262-272
        • Price R.G.
        The role of NAG (N-acetyl-beta-d-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity.
        Clin Nephrol. 1992; 38: S14-S19
        • Di Mario U.
        • Morano S.
        • Cancelli A.
        • et al.
        New parameters to monitor the progression of diabetic nephropathy.
        Am J Kidney Dis. 1989; 13: 45-48
        • Monteleone G.
        • Cristina G.
        • Parrello T.
        • et al.
        Altered IgG(4) renal clearance in patients with inflammatory bowel diseases. Evidence for a subclinical impairment of protein charge renal selectivity.
        Nephrol Dial Transplant. 2000; 15: 498-501
        • Dehmer C.
        • Greinwald R.
        • Löffler J.
        • et al.
        No dose-dependent tubulotoxicity of 5-aminosalicylic acid: a prospective study in patients with inflammatory bowel diseases.
        Int J Colorectal Dis. 2003; 18: 406-412
        • Patel H.
        • Barr A.
        • Jeejeebhoy K.N.
        Renal effects of long-term treatment with 5-aminosalicylic acid.
        Can J Gastroenterol. 2009; 23: 170-176
        • de Jong D.J.
        • Tielen J.
        • Habraken C.M.
        • et al.
        5-Aminosalicylates and effects on renal function in patients with Crohn's disease.
        Inflamm Bowel Dis. 2005; 11: 972-976
        • Delanaye P.
        • Cavalier E.
        • Pottel H.
        Serum creatinine: not so simple!.
        Nephron. 2017; 136: 302-308
        • Levey A.S.
        • Inker L.A.
        Assessment of glomerular filtration rate in health and disease: a state of the art review.
        Clin Pharmacol Ther. 2017; 102: 405-419
        • Stevens L.A.
        • Nolin T.D.
        • Richardson M.M.
        • et al.
        Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations.
        Am J Kidney Dis. 2009; 54: 33-42
        • Tekin F.
        • Ozutemiz O.
        • Ilter T.
        5-aminosalicylates in inflammatory bowel disease and chronic renal failure.
        Aliment Pharmacol Ther. 2005; 22: 579
        • Biancone L.
        • Annese V.
        • Ardizzone S.
        • et al.
        Safety of treatments for inflammatory bowel disease: clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
        Dig Liver Dis. 2017; 49: 338-358
      1. GETAID. Dérivés aminosalicylés: rowasa®, Fivasa®, Pentasa®, Dipentum®, Salazopyrine®, Quadrasa®. Accessed August 2020. https://www.getaid.org/fiches-medicament/les-derives-aminosalicyles-rowasa-fivasa-pentasa-dipentum-salazopyrine-quadrasa

      2. Food and Drug Administration. Mesalamine prescribing information as of 05/2010. Accessed August 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019651s023lbl.pdf

      3. Food and Drug Administration. Mesalamine prescribing information as of 07/2019. Accessed August 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020049s032lbl.pdf